Search the Newsreel

Why Black Diamond Group Limited stock is rising today

Diamondback Energy Rose Almost 6% in a Day. Here’s Where the Stock Could Go in 2026

Diamondback Energy (FANG) saw a nearly 6% stock jump, largely driven by rising oil prices, after reporting strong Q2 results that beat revenue and earnings estimates. The company's management has focused on financial flexibility, debt reduction, and strategic share repurchases, rather than a fixed …

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger

Earnings Call Insights: DiaMedica Therapeutics (DMAC) Q2 2026 MANAGEMENT VIEW * “Q2 was an important quarter for DiaMedica with progress across DM199 in early onset fetal growth restriction, preeclampsia and acute ischemic stroke,” said President, CEO & Director Dietrich Pauls, highlighting “enrollment has been …

HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC)

HC Wainwright has reaffirmed its "Buy" rating for DiaMedica Therapeutics (NASDAQ:DMAC) and maintained a $12 price target, indicating a potential 74.8% upside. The company recently reported a quarterly loss of $0.19 per share, exceeding analyst expectations. DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, focuses on …

Could Black Diamond (TSX:BDI) Outperform Canada’s Growth Market?

Why Did Diamondback Energy (FANG) Stock Climb After Its Latest Update?

DiaMedica Therapeutics Q2 Earnings Call Highlights

DiaMedica Therapeutics provided updates on its Q2 progress, focusing on advancing DM199 for early-onset fetal growth restriction (FGR), preeclampsia, and acute ischemic stroke. The company completed enrollment for the first cohort of its Phase II FGR study and presented positive blood pressure reduction data …

Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance

DiaMedica Therapeutics reported a Q2 2026 loss that matched Wall Street forecasts, with adjusted earnings of negative $0.19 per share and no revenue. The biotech company is advancing its clinical programs in preeclampsia, fetal growth restriction, and stroke, noting progress in all three areas. …

Diamond Power Infrastructure schedules Q1FY27 earnings call

Diamondback Energy (FANG) Q2 2026 Earnings Call Transcript

What's Going On With Black Diamond Group Limited Stock Monday?

DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Market Pricing Reflects High Growth Expectations

DiaMedica Therapeutics (DMAC) announced positive interim results from its Phase 2 clinical trial for DM199 in preeclampsia treatment, highlighting its potential in various ischemic diseases. Despite being unprofitable and lacking sales, the company's high Price-to-Sales ratio and strong momentum reflect significant market expectations for …

DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise

DiaMedica Therapeutics Inc. reported a Q2 2026 net loss of $10.1 million, an increase from $7.7 million in the prior year, primarily due to a 41% rise in R&D expenses. Despite the widening loss, the company made significant clinical progress with its lead candidate …

DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly earnings per share (EPS) of negative $0.19, exceeding analyst estimates by $0.01. Despite this beat, shares fell 1.5% to $6.65, and the company's market capitalization stands at approximately $358.3 million, significantly below its 52-week high. Analyst sentiment is a …

DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported a wider net loss of $20.2 million for the first half of 2026, compared to $15.4 million a year earlier, primarily due to increased research and development (R&D) spending. R&D expenses rose to $16.1 million as the company …

Wall Street Divided on Diamondback Energy as Jefferies and Bernstein Issue Diverging Price Target Revisions

Wall Street analysts are showing mixed signals on Diamondback Energy (FANG), with Jefferies raising its price target to $205 while maintaining a Hold rating, and Bernstein lowering its target to $221 but keeping an Outperform rating. Despite these differing revisions, the overall analyst consensus, …

Diamondback Energy On Pace for Largest Percent Increase Since April 2025 -- Data Talk

Diamondback Energy, Inc. (FANG) is experiencing a significant surge, currently up 5.35% at $198.10, putting it on track for its largest percentage increase since April 2025. This performance makes it the ninth best performer in the S&P 500 and fourth best in the Nasdaq …

Lucara Diamond Q2 Earnings and Revenue Fall

Why Lucara Diamond Corp stock is rising today

Diamondback Energy (NASDAQ:FANG) Given New $220.00 Price Target at Citigroup

Citigroup has adjusted its price target for Diamondback Energy (NASDAQ:FANG) to $220.00, a slight decrease from $221.00, while maintaining a "buy" rating. This new target suggests a potential upside of 12.58% from the stock's last close. The company recently surpassed quarterly earnings and revenue …

Diamondback Energy’s new Midland Basin wells’ results are rising, not sputtering out. SM Energy’s Midland results are overcoming the E&P’s “science-heavy” spell.

The article highlights that Diamondback Energy and SM Energy are demonstrating sustained and improving well productivity in the Midland Basin, defying expectations of degradation. Despite a decrease in active rig counts, Permian tight oil and shale production remain robust due to efficiency gains, longer …

SKYGOLD: Q1 FY 2027 delivered robust revenue and margin growth, with strong cash flow and export momentum

SKYGOLD: Q1 FY 2027 delivered 78% revenue growth, margin gains, and positive cash flow, supporting strong long-term targets

Sky Gold and Diamonds posts strong Q1, revenue jumps 78% as profits more than double

Diamondback Energy Inc Stock Price Live, Charts & News - The Economic Times

This article provides a live overview of Diamondback Energy Inc. (FANG) stock, including its current price, daily performance, and key financial metrics. It details the company's market capitalization, P/E ratio, dividend yield, and historical returns, along with quarterly balance sheets, income statements, and cash …

Sky Gold & Diamonds Q1 Results: Earnings Call Scheduled for 10 Aug 2026

SKYGOLD: Q1 FY27 revenue jumped 77.9% YoY and PAT soared 140.7% YoY, with margins expanding

Sky Gold & Diamonds: Q1 FY27 Revenue Up 78% to ₹2,012.8 Cr

SKYGOLD: Strong revenue and profit growth in Q1 FY27, with cyber fraud loss addressed by new controls

Lucara Holds Guidance as Q2 Revenue Dips, Advances Karowe Underground Project

Diamondrock Hospitality Company (DRH) Stock Forecasts

Argus has increased its rating for Diamondrock Hospitality Company (DRH) to a BUY, as of August 5, 2026. DRH is a real estate investment trust focused on owning, managing, and renovating full-service hotel properties in the United States. To access the full report and …

Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX

Renaissance Technologies LLC significantly increased its stake in Black Diamond Therapeutics (NASDAQ:BDTX) by 73.1% in the first quarter, holding 1.64 million shares valued at $3.50 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 95.47%. The company reported a …

Diamondback Energy (NASDAQ:FANG) Rating Increased to Buy at Wall Street Zen

Wall Street Zen has upgraded Diamondback Energy (NASDAQ:FANG) from a "hold" to a "buy" rating, aligning with the broader analyst consensus and an average price target of $220.75. The company recently reported strong quarterly earnings, beating EPS and revenue estimates. Despite this positive analyst …

Lucara Diamond Q2 Results: EPS beats estimate, sales drop 6%

Q1 Earnings Forecast for BDTX Issued By HC Wainwright

HC Wainwright has issued its Q1 2027 earnings forecast for Black Diamond Therapeutics (NASDAQ:BDTX), projecting a loss of $0.22 per share and maintaining a "Buy" rating. The firm also provided full-year 2027 estimates at a loss of $0.96 per share. This follows Black Diamond …

Black Diamond Therapeutics Inc (BDTX) Stock News Today